HOUSTON - TelAve -- Respiratory Technology Corporation ("Restech") is pleased to announce the acquisition of the assets of Somna Therapeutics LLC. Somna provides medical devices for the treatment of laryngopharyngeal reflux (LPR) and extraesophageal acid reflux diseases. Their key product, the Reflux Band, is a non-pharmacologic, wearable device that prevents reflux into the larynx, pharynx, and lungs.

This transaction represents Restech's second significant acquisition since 2018 when it acquired the assets of Mederi Therapeutics LLC. According to Thomas Ball, Restech Vice President of Clinical Affairs, "Restech continues to expand its continuum of care for reflux related illnesses. Our core Dx-pH diagnostic product and Stretta endoscopic procedure are well respected among physicians, and our recently released PepsinCheck direct to consumer diagnostic test has been extremely well-received. With the anticipated re-launch of the Reflux Band, we will add another non-medicative reflux relief option. Globally, patients are eager to play an increasingly active role in their medical care, and Restech is there to empower them with the solutions they need."

More on TelAve News

• 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment
• Security Alert: TZNXG Warns Investors About "Fund Recovery" Scams
• Assent Unveils Extended Producer Responsibility Packaging Solution to Simplify Compliance with Expanding Packaging Laws
• KatalisCoin: "Too Secure" for Bad Actors - Platform Embraces "Excessive Compliance" Criticism
• Keyanb Exchange Implements Enhanced Security Protocols Amid Industry-Wide Trust Challenges

About Somna Therapeutics LLC
Based in Germantown, Wisconsin, Somna Therapeutics LLC, was founded in 2012 by Tom Shannon, Nick Maris, Jeff Harris, and Reza Shaker, MD, in partnership with the Medical College of Wisconsin. Reflux Band was originally introduced as the Reza Band — named for its inventor, Reza Shaker, MD. Its name was changed to Reflux Band to better align the product with the condition it helps relieve — LPR due to acid reflux into the throat and lungs. The product is FDA Cleared and CE marked as a class I, over-the-counter non-pharmacologic LPR solution.

About Restech
Restech, formed in 2003 is based in Houston, Texas. We believe there is a better way to manage reflux. It all started in a meeting with world renowned gastroenterologists who told our engineers a little secret: the market needed a pH sensor that works outside of the esophagus. Our team accepted the challenge and launched the first real-time sensor that could function accurately in a non-liquid environment. Since then, we've been on a mission to rethink reflux, ensuring we understand the ins and outs of the disease state and industry. Although it is highly complex, we are passionate about bringing simple, effective reflux solutions to patients and clinicians around the world. Our rapid growth reflects our dedication and passion–developing and seeking out new products across the reflux diagnostic and therapeutic continuum from surgical to home health.

More on TelAve News

• TSWHZC Platform Combines Automated Portfolio Management with Proof of Reserves for Brazil Market Entry
• AureaVault Positions Digital Asset Infrastructure for Shifting Monetary Policy Environment
• JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
• New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
• Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections